[1] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 肝脏, 2015, 10: 750-767.
[2] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol, 2014, 109: 950-966.
[3] Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
[4] Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-Ⅱ. An original model for validation of drugcausality assessment methods: case reports with positive rechallenge. J Clin Epidemiol, 1993, 46:1331-136.
[5] http://www.livertox.nih.gov/rucam.html.
[6] Aithal G, Watkins P, Andrade R, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, 89:806-815.
[7] Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci, 2016, 17. pii: E14. doi: 10.3390/ijms17010014.
[8] Hunt CM, Papay JI, Stanulovic V, et al. Drug rechallenge following drug-induced liver injury. Hepatology, 2017, 66: 646-654.
[9] Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and metaanalysis of clinical trials in advanced cancer patients. Eur J Cancer, 2015, 51:1293-1302.
[10] US Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. July 2009. Available at: <http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf>. [accessed 18.09.17].
[11] 于乐成, 何长伦, 侯金林. 药物诱导性肝损伤生物标志物研究进展. 实用肝脏病杂志, 2014, 17:564-568.
[12] Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf, 2013, 36:491-503.
[13] Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug-induced liver injury (ATLI) in China. PLoS One, 2011, 6:e21836. doi: 10.1371/journal.pone.0021836.
[14] Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis, 2010, 50: 833-839.
[15] Babalk A, Arda H, Bakrc N, et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks, 2012, 60:136-144.
[16] Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol, 2013, 3:37-49.
[17] 于乐成, 范晔, 陈成伟. 药物性肝损伤慢性化判断标准: 3或6个月还是1年? 肝脏, 2017, 22: 97-100.
[18] 于乐成, 陈成伟. 新版RUCAM:药物和草药诱导性肝损伤的重要评估工具. 肝脏, 2016, 21: 493-500.
[19] 于乐成,茅益民,陈成伟. 对新版RUCAM量表的评价和几点商榷意见. 肝脏, 2016, 21: 432-433. |
